SCHEMBL2548099

SCHEMBL2548099

Nc1ncnc2c1ncn2CC1COP(=O)(Oc2ccccc2)CO1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.44
PI4KA P42356 2/20 0.44
PI4K2B Q8TCG2 2/20 0.44
PI4K2A Q9BTU6 2/20 0.44
PI4KB Q9UBF8 2/20 0.44
EGFR P00533 2/20 0.43
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.41
FGFR1 P11362 1/20 0.38
PIK3CD O00329 2/20 0.38
NSD3 Q9BZ95 5/20 0.38
NSD2 O96028 4/20 0.38
STING1 Q86WV6 2/20 0.38
ADORA1 P30542 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA9 Q16790 1/20 0.38
PIK3R1 P27986 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2548233 0.83 ALDH1A1 (0.39) EGFRLMNASMN1; SMN2NSD3STING1
SCHEMBL2548230 0.82 MARS1 (0.39) LMNASMN1; SMN2NSD3STING1ALDH1A1
SCHEMBL10047656 0.80 ADORA2A (0.47) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL10073562 0.80 FGFR1 (0.54) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL12238556 0.79 ATM (0.42) SMN1; SMN2NSD2STING1CA1CA2
SCHEMBL2541239 0.79 ATM (0.42) SMN1; SMN2NSD2STING1CA1CA2
SCHEMBL2543337 0.79 ADK (0.36) ADORA2ALMNASMN1; SMN2STING1ADORA1
SCHEMBL15633431 0.77 FGFR1 (0.39) FGFR1ALDH1A1
SCHEMBL15633590 0.77 ATM (0.40) FGFR1ALDH1A1
SCHEMBL15633610 0.77 FGFR1 (0.39) FGFR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940313-B2 Tyrosine-based prodrugs of antiviral agents UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2015-01-27 US disclosed
US-20110263535-A1 TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS UNIVERSITY OF SOUTHERN CALIFORNIA 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263535-A1 TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS TYMP, MTAP, TK1 ADORA2A 170/4885PI4KA 1684/4885PI4K2B 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.